Targeted therapeutic progression of EGFR mutation in non-small cell lung cancer with brain metastasis

VernacularTitle:EGFR突变非小细胞肺癌脑转移靶向治疗进展
Author: Yijun LUO ¹ ; Weirong YAO ; Xiaoli WANG
Author Information

1. 江西省人民医院（南昌医学院第一附属医院）肿瘤科，南昌　330000
Keywords: Carcinoma, non-small-cell lung; Neoplasm metastasis; Radiotherapy; Molecular targeted therapy; Drug therapy, combination
From: Journal of International Oncology 2024;51(11):717-722
CountryChina
Language:Chinese
Abstract: Patients with brain metastases from non-small cell lung cancer (NSCLC) generally have a poor prognosis. Tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of patients with sensitizing mutations in the epidermal growth factor receptor (EGFR) gene. Combining TKIs with other treatments such as radiotherapy, chemotherapy, and anti-angiogenic therapy can improve survival of patients with EGFR-mutant NSCLC brain metastases. However, more in-depth clinical studies are needed to determine the best combination strategies and to identify which patient groups will benefit the most from these approaches.